These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Thiopurines and myeloid disorders: is more caution needed when treating inflammatory bowel disease patients?
    Author: Lopez A, Beaugerie L, Peyrin-Biroulet L.
    Journal: Expert Rev Clin Immunol; 2014 Dec; 10(12):1563-5. PubMed ID: 25362886.
    Abstract:
    Thiopurines remain the backbone therapy of inflammatory bowel diseases (IBD). However, these drugs have potential mutagenic and carcinogenic effects, especially when prescribed for a long time. In addition to the increased risk of lymphoma and non-melanoma skin cancer, recent data suggest that risk of myeloid disorder is increased in IBD patients with past exposure to thiopurines. Even if individual risk is low, practitioners who take care of IBD patients should be aware of this potential complication of thiopurines treatment.
    [Abstract] [Full Text] [Related] [New Search]